Mark J. Gergen - 01 Feb 2023 Form 4 Insider Report for Poseida Therapeutics, Inc.

Role
President and CEO, Director
Signature
/s/ Harry J. Leonhardt, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
01 Feb 2023
Net transactions value
-$222,733
Form type
4
Filing time
03 Feb 2023, 15:16:46 UTC
Previous filing
01 Feb 2022
Next filing
02 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PSTX Common Stock Tax liability $222,733 -31,819 -8.8% $7.00 330,314 01 Feb 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on February 1, 2022.
F2 Includes 3,000 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on March 18, 2022 and 1,933 shares acquired by the Reporting Person under the ESPP on September 20, 2022.